Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
85 hedge funds and large institutions have $87.8M invested in Enzo Biochem, Inc. in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 14 closing their positions.
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0.68% more ownership
Funds ownership: 67.39% → 68.07% (+0.68%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $88.4M → $87.8M (-$663K)
7% less funds holding
Funds holding: 91 → 85 (-6)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
+$4.68M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.68M |
| 3 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$2.6M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$871K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$383K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$9.51M |
| 2 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$358K |
| 3 |
BlackRock
New York
|
-$298K |
| 4 |
Morgan Stanley
New York
|
-$295K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$259K |
ENZ Hedge Fund Activity: Q1 2019 in Review
85 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2019, worth a combined $87.8M — down 0.75% from $88.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ENZ and 8 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 29 added.
The largest buyer was Harbert Fund Advisors, adding an estimated $4.68M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $9.51M.
- 85 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2019, down from 91 in Q4 2018.
- Funds reported $87.8M of Enzo Biochem, Inc. stock for Q1 2019, down 0.75% quarter-over-quarter.
- 8 funds opened new Enzo Biochem, Inc. positions in Q1 2019 and 14 closed out, a net change of -6 holders.
- The largest Enzo Biochem, Inc. buyer in Q1 2019 was Harbert Fund Advisors, an estimated $4.68M added.
- The largest Enzo Biochem, Inc. seller in Q1 2019 was Manulife (Manufacturers Life Insurance), an estimated $9.51M sold.
Based on aggregated 13F filings for Q1 2019.